PeptideStack
5.2kquestions
20kanswers
220users

How do I reconcile 97.9% from VendorInvestigate with 96.8% from the supplier?

Asked 29 Nov 2024Modified 17 months agoViewed 17k times
13

Concretely: 97.9% · VendorInvestigate · 96.8%.

I think I have a problem. I am not yet sure whether it is a real problem or a measurement artefact.

I want to know whether this is recoverable or whether the honest answer is to write it off.

Should I be treating this as a failure or as noise?

purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

833 questions
batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

910 questions
coa
coa

Certificates of analysis: what fields a useful one carries, how to tell a real analytical report from a marketing document, batch and lot…

771 questions
vendor-investigate
vendor-investigate

VendorInvestigate, an independent vendor review and verification service. Use this tag for questions about its verification criteria, what a…

113 questions
shareeditfollowflag
EV
askedekaterina_volk21k2829 Nov 2024
Is the comparison against a supplier certificate or against a second independent result? – assay_blank 34 days ago
8Voting to keep this open — it is more specific than it first looks. – ahmed_zerouali 9 months ago
add a comment

5 Answers

Accepted answer first, then by votes
26

Accepted answer

1.1 percentage points, and the direction is the informative half. VendorInvestigate reports 97.9 per cent and the certificate 96.8, so the independent figure is higher. As impurity that is 2.1 per cent against 3.2 — 0.66 times as much unassigned area, which is the unusual direction and worth a second look at the integration. Method differences usually make the independent number the lower one, so an independent result above the certificate points at integration limits, a different wavelength, or a different definition of the main peak rather than at a better vial. Ask both parties for the method section before you decide which figure is wrong, because the answer is often neither.

The single most important distinction is between what purity measures — the fraction of detected material that is your target — and what you actually want to know — how much of the material in the vial is your target.

Detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.

Mechanically, integration of the shoulder — whether you use perpendicular drop or tangent skim — determines what area gets assigned to the main peak versus the impurity table.

Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.

One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.

Compare purity within a single laboratory on the same method, never across laboratories.

edited 7 Feb 2025 by p_mkhize — expanded the table to cover the lower concentration

shareimprove this answerflag
PM
answered · acceptedp_mkhize58k23819 Jan 2025
Sponsored

Janoshik Analytical - Independent Third-Party Testing

HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.

Submit a sample
Sponsored — paired listing

GL Biochem (Shanghai) Ltd. - Direct Synthesis

Founded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.

Visit GL Biochem
30

Mechanically, the method matters more than the vial, which is why specifying a method buys you far more than changing suppliers does.

Buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.

Mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.

Inter-laboratory studies on identical peptide material routinely find half-a-per-cent to a full-per-cent spreads in reported purity on the same sample.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

shareimprove this answerflag
PS
answeredplunger_stop13k2710 Feb 2025
6Do you have the chromatogram for this, or just the summary figure? – forty_two_c 1 days ago
7Same experience here, different supplier. – Dr_Tomas_Kral 2 months ago
add a comment
19

Gradient slope is the most powerful parameter and almost nobody mentions it, which is why two reports on the same material disagree by a point.

Column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.

Tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.

The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.

If you are ranking vendors, specify a method and have all samples tested at the same place.

shareimprove this answerflag
DB
answeredDr_Fatima_Belkacem18k2622 Feb 2025
2I would gently push back on the second point — inter-laboratory spread is wider than stated. – laminar_bench 6 months ago
add a comment
13

Worth being precise here: area percentage is not mass percentage, and conflating the two is the most common misreading of a purity figure.

Mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.

Published side-by-side method comparisons show that a two-point difference in purity on the same vial is easily explained by method choice alone.

The limitation is that single-digit micro-impurities become invisible at typical reporting thresholds, so "no impurities detected" means "none above one in two thousand."

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

shareimprove this answerflag
KA
answeredkwn_analytical147k35828 Dec 2024
3Thank you — this is the answer I was looking for. – sian_llewellyn 3 months ago
4Adding for future readers: the certificate should carry the lot number, not just a batch code. – elke_brunner 5 months ago
add a comment
10

The honest answer is that the achievable range of plausible purity figures for a given vial is wider than most people expect.

Gradient slope controls resolution, and gentler slopes resolve co-eluting impurities into separate peaks — so the better method reports the worse purity number.

The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.

I would be careful about over-reading a single measurement — treat it as a data point, not as ground truth.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.

edited 8 Feb 2025 by tandem_gradient — removed a claim I could not source

shareimprove this answerflag
TG
answeredtandem_gradient61k24831 Jan 2025
Adding a vote because this deserves more of them. – claudia_ferrante 5 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.